Eisai
4523.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥825.4bn | ¥789.4bn | ¥741.8bn | ¥744.4bn | ¥756.2bn | ¥645.9bn |
| Operating income | ¥44.1bn | ¥54.4bn | ¥53.4bn | ¥40.0bn | ¥53.8bn | ¥51.5bn |
| Net income (owners) | ¥38.6bn | ¥46.4bn | ¥42.4bn | ¥55.4bn | ¥48.0bn | ¥41.9bn |
| Total assets | ¥1.45T | ¥1.39T | ¥1.39T | ¥1.26T | ¥1.24T | ¥1.09T |
| Net assets / equity | ¥925.1bn | ¥866.0bn | ¥899.0bn | ¥822.6bn | ¥771.5bn | ¥726.4bn |
| Operating cash flow | ¥61.3bn | ¥30.1bn | ¥56.0bn | −¥1.8bn | ¥117.6bn | ¥73.1bn |
| EPS (basic) | ¥136.78 | ¥163.76 | ¥147.86 | ¥193.31 | ¥167.27 | ¥146.34 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 77 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 77 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Americas | ¥300.4bn | ¥174.4bn |
| China | ¥130.7bn | ¥59.3bn |
| East Asia Global South | ¥68.8bn | ¥30.2bn |
| EMEA | ¥81.5bn | ¥30.4bn |
| Japan | ¥229.2bn | ¥73.0bn |
| Other segments | ¥14.6bn | ¥4.5bn |
| Total | ¥810.8bn | ¥367.3bn |
| Total | ¥825.4bn | ¥371.8bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.